CADL

Candel TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$14.00

+66.3% vs current

Most likely

Base case

45%

Probability

Target price

$9.00

+6.9% vs current

B-

Bear case

30%

Probability

Target price

$4.50

-46.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

Primary-source newsflow turned more constructive after the May 14 earnings release and May 15 AUA update, but the setup still looks like a monitoring story rather than a clean post-print re-rate. CADL closed at $8.77 on May 15, 2026, with a $7.79 to $9.19 intraday range and about a 1.9% decline versus the prior close, which suggests volatile digestion rather than decisive endorsement. Trusted analyst revision data after the print was not available, social context was not provided, and the deterministic prior remains negative with only moderate evidence quality, so confidence should stay restrained.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystAUA phase 3 prostate update is constructive but still needs broader BLA-probability digestionHigh impact

Candel furnished extended follow-up data from the phase 3 aglatimagene prostate trial at AUA on May 15, 2026, with the investor deck showing a hazard ratio of 0.61 and a 39% improvement in prostate cancer-specific disease-free survival after extended follow-up; that strengthens the filing narrative, but the market reaction was volatile rather than a clear re-rate, so the next few sessions matter for whether investors treat the update as incremental or BLA-relevant de-risking [#8-K-2026-05-15].

2026-06-30eventJune 2026 NSCLC phase 3 initiation is the clearest external execution checkpointHigh impact

In its May 14, 2026 first-quarter update, Candel said it plans to initiate the pivotal phase 3 trial of aglatimagene in metastatic non-squamous NSCLC with progressive disease despite ICI treatment in June 2026; hitting that start date would support platform credibility beyond prostate cancer, while delay would weaken the broader pipeline case [#8-K-2026-05-14].

2026-12-31eventQ4 2026 planned prostate BLA remains the main value-creation milestoneHigh impact

Management reiterated that a BLA submission for aglatimagene in localized intermediate- to high-risk prostate cancer is planned for Q4 2026, with Q3 2026 biomarker data still expected beforehand; if the filing path holds, CADL can continue shifting from a binary clinical story toward a pre-commercial regulatory story, but any slippage would likely pressure the stock because commercial-readiness spending is already rising [#8-K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology